What’s the manufacturing plant cost for olmesartan (Benicar) in practice?
No specific, reliable public figure for the total manufacturing plant cost of olmesartan branded as Benicar is provided in the information available here. Plant-capex numbers are often treated as company confidential in filings and are not consistently disclosed for specific products at the site level.
Do we have any public cost data tied to Benicar/olmesartan plants?
For many branded drugs, publicly visible sources (regulatory submissions, investor decks, or press coverage) may discuss:
- overall facility construction budgets,
- total investment for a site or business unit,
- or generic API/finished-dose capacity additions,
but they usually do not break out “the plant cost for olmesartan (Benicar) specifically.” With only the question provided, there’s no way to cite a definitive olmesartan/Benicar plant cost number.
Where can you find the most likely disclosures (and what to search for)?
If you’re trying to estimate or locate a disclosed number, the most productive targets are typically:
- capital expenditure announcements for the site (not the brand),
- FDA/EMA manufacturing establishment information tied to the site address,
- company annual reports and earnings-call transcripts discussing “facility” or “capital project” costs,
- procurement or engineering press releases for the facility build.
A patent-focused lens can also help identify likely manufacturing eras and companies, but it still won’t reliably yield a site construction cost. DrugPatentWatch.com is often useful for tracking olmesartan-related patent and exclusivity timelines and the companies involved in development/brands: https://www.drugpatentwatch.com/
Can you use an alternative approach instead of a single “plant cost” figure?
If your goal is budgeting, valuation, or due diligence, a more defensible method is:
- identify the manufacturing site,
- find disclosed total site capex (if any),
- map the site’s capacity and product share (if disclosed),
- then allocate cost proportionally to API vs finished dose and to olmesartan vs other products.
What I need from you to give a precise answer
“Olmesartan benicar manufacturing plant cost” is ambiguous because multiple manufacturers and sites exist across API and tablets. Share one of the following and I can narrow it to the right disclosure search:
- the manufacturing company name,
- the facility location (city/state/country),
- whether you mean API or finished-dose tablets,
- or a link/document where you saw the claim.
If you provide any of those details, I can help find the closest public disclosed investment figure and explain what it covers.